The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery
- 31 August 1996
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Clinical Anesthesia
- Vol. 8 (5), 357-360
- https://doi.org/10.1016/0952-8180(96)00080-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Use of aprotinin in knee replacement surgeryBritish Journal of Anaesthesia, 1994
- Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical PatientsAnesthesiology, 1994
- High-dose Aprotinin Reduces Blood Loss in Patients Undergoing Total Hip Replacement SurgeryAnesthesiology, 1994
- Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patientsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1993
- Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cellsMolecular Immunology, 1993
- Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood savingThe Annals of Thoracic Surgery, 1992
- High-dose aprotinin therapy: A review of the first five years' experienceJournal of Cardiothoracic and Vascular Anesthesia, 1992
- EFFECT OF APROTININ ON INTRAOPERATIVE BLEEDING AND FIBRINOLYSIS IN LIVER TRANSPLANTATIONThe Lancet, 1989
- PLATELET PRESERVATION BY APROTININ DURING CARDIOPULMONARY BYPASSThe Lancet, 1988
- EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERYThe Lancet, 1987